

1    **Development and comparison of a novel multiple cross displacement amplification**  
2    **(MCDA) assay with other nucleic acid amplification methods for SARS-CoV-2 detection**

3

4    Laurence Don Wai Luu<sup>1</sup>, Michael Payne<sup>1</sup>, Xiaomei Zhang<sup>1</sup>, Lijuan Luo<sup>1</sup> and Ruiting Lan<sup>1\*</sup>

5

6    <sup>1</sup>School of Biotechnology and Biomolecular Sciences, University of New South Wales,  
7    Sydney, New South Wales, Australia

8

9    \*Corresponding Author

10   Email: [r.lan@unsw.edu.au](mailto:r.lan@unsw.edu.au)

11   Phone: 61-2-9385 2095

12   Fax: 61-2-9385 1483

13

14   Abstract word count: 200

15

16   Keywords: COVID-19, SARS-CoV-2, multiple cross displacement amplification, isothermal  
17   amplification, loop-mediated amplification, rt-PCR, MCDA, LAMP, sensitivity, Coronavirus

18 **Abstract**

19 The development of alternative isothermal amplification assays including multiple cross  
20 displacement amplification (MCDA) may address speed and portability limitations of real-  
21 time PCR (rt-PCR) methods for SARS-CoV-2 detection. We developed a novel SARS-CoV-  
22 2 MCDA assay and compared its speed and sensitivity to loop-mediated isothermal  
23 amplification (LAMP) and rt-PCR. Two MCDA assays targeting SARS-CoV-2 N gene and  
24 ORF1ab was designed. The fastest time to detection and sensitivity of MCDA was compared  
25 to LAMP and rt-PCR using DNA standards and transcribed RNA. For N gene, MCDA was  
26 faster than LAMP and rt-PCR by 10 and 20 minutes, respectively with fastest time to  
27 detection at 5.2 minutes. rt-PCR had highest sensitivity with limit of detection at 10 copies/ $\mu$ l  
28 compared with MCDA (100 copies/ $\mu$ l) and LAMP (500 copies/ $\mu$ l). For ORF1ab, MCDA and  
29 LAMP had similar speed with fastest time to detection at 9.7 and 8.4 minutes, respectively.  
30 LAMP was more sensitive for ORF1ab detection with 50 copies/ $\mu$ l compared to MCDA (500  
31 copies/ $\mu$ l). In conclusion, different nucleic acid amplification methods provide different  
32 advantages. MCDA is the fastest nucleic acid amplification method for SARS-CoV-2 while  
33 rt-PCR is the most sensitive. These advantages should be considered when determining the  
34 most suitable nucleic acid amplification methods for different applications.

35

## 36 **Introduction**

37 Rapid, portable and highly sensitive assays are essential to controlling the COVID-19  
38 pandemic. Real-time-PCR (rt-PCR) is the gold standard for detection of SARS-CoV-2  
39 genetic material<sup>1</sup>. However, rt-PCR requires trained personnel, advanced equipment and  
40 relatively long assay times making it unsuitable for large-scale community screening. Other  
41 tests developed include serological assays that rely on IgM/IgG antibodies which takes ~5  
42 days to appear after symptom onset making them unsuitable for rapid early detection<sup>2</sup>.

43 The development of alternative nucleic acid amplification methods including loop-mediated  
44 isothermal amplification (LAMP) may offer improved speed, sensitivity and portability for  
45 SARS-CoV-2 detection<sup>3</sup>. Another isothermal nucleic acid amplification method, called  
46 multiple cross displacement amplification (MCDA) which uses 10 primers instead of six, has  
47 also been suggested to have even higher sensitivity and speed than LAMP but has not yet  
48 been developed for SARS-CoV-2 detection<sup>4,5</sup>.

49 Despite claims of increased speed and sensitivity from isothermal amplification methods, no  
50 study has directly compared the speed and sensitivity of these three different nucleic acid  
51 amplification methods. Hence, here we developed an MCDA assay for SARS-CoV-2  
52 detection and compared its speed and sensitivity to existing LAMP and rt-PCR methods.

53

## 54 **Methods**

### 55 **MCDA target gene selection**

56 To identify target genes with highly conserved regions and a suitable GC-content for MCDA,  
57 1,216 SARS-CoV-2 genomes deposited in GISAID (all available complete, high coverage  
58 genomes (>29,000 bp) with low coverage flags excluded up until March 26, 2020)<sup>6</sup> were  
59 aligned against the SARS-CoV-2 reference genome: NC\_045512.2 using Snippy (v4.3.6)

60 with the -ctgs flag and default settings (<https://github.com/tseemann/snippy>). A sliding  
61 window approach was then applied to identify conserved 300bp windows with GC content  
62 >43%, low SNP number, and low total SNP number (total SNPs was defined as the number  
63 of strains with a SNP in a given window). Three 300 bp conserved regions were identified  
64 and selected for MCDA primer design with two regions in ORF1ab (NC\_045512.2: 515-831  
65 and 12968-13288) and one in the *N* gene (NC\_045512.2: 28345-28647).

66

### 67 **MCDA primer design**

68 For each region, 4 sets of MCDA primers were designed as previously described<sup>5</sup>. Each  
69 primer set consisted of 2 cross-primers (CP1/CP2), 2 displacement primers (F1/F2) and 6  
70 amplification primers (C1/C2, D1/D2, R1/R2) (Supplementary Table 1). Non-specific primer  
71 binding was assessed using BLASTN against 14 non-SARS-CoV-2 coronaviruses used in  
72 Lamb *et al.*<sup>7</sup>, human genome (hg19) and 11 other common bacterial and viral respiratory  
73 pathogen/microbiome species.

74

### 75 **Preparation of DNA/RNA standards**

76 For each region, ~500 bp gene fragments for ORF1ab (NC\_045512.2: 416-931 and 12869-  
77 13388) and *N* gene (NC\_045512.2: 28246-28747) were synthesised with an additional 100 bp  
78 up and downstream of the target region (ThermoFisher) (Supplementary Table 2). Each  
79 fragment contained a T7 promoter for transcription and M13 adapters for amplification.  
80 Seven DNA standards from synthesised gene fragments were prepared for ORF1ab (100,000,  
81 10,000, 5000, 1000, 500, 250 and 100 copies/ $\mu$ l) while eight DNA standards were prepared  
82 for the *N* gene (100,000, 10,000, 5000, 1000, 500, 250, 100 and 10 copies/ $\mu$ l).

83 For RNA, 1 pg of synthesised gene fragments were transcribed overnight at 37°C using T7  
84 RNA polymerase (Sigma). Overnight DNA digestion was performed using the turbo DNA

85 free kit (ThermoFisher) and further treated with DNase I (NEB) until all traces of DNA were  
86 removed. Complete DNA removal was confirmed after each round of DNase treatment using  
87 rt-PCR with the SensiFAST SYBR kit (Bioline) and F1/R1 MCDA primers (Supplementary  
88 Table 1). The transcribed RNA was serially diluted and used as input. Since the amount of  
89 RNA transcribed was below the 250 pg/ $\mu$ l limit of detection for qubit HS RNA assay  
90 (ThermoFisher), the input RNA copy number could not be determined. Therefore, the lowest  
91 detectable dilutions were used for sensitivity comparison.

92

### 93 **Initial evaluation of MCDA primer sets and optimisation of isothermal amplification** 94 **temperature**

95 MCDA reactions were performed using the WarmStart LAMP (DNA and RNA) kit (NEB)  
96 which contains a warmstart RTx reverse transcriptase and Bst2.0 polymerase for  
97 simultaneous reverse transcription and isothermal amplification. Antarctic thermolabile UDG  
98 was also added in each reaction to prevent carryover contamination.

99

100 For each primer set, a primer mix containing: 3.3  $\mu$ M of F1 and F2, 6.67  $\mu$ M of C1 and C2,  
101 10  $\mu$ M of R1, R2, D1 and D2 and 20  $\mu$ M of CP1 and CP2 was used. Standard desalting  
102 purified primers were used for the initial evaluation and optimisation tests while HPLC  
103 purified primers were used for sensitivity and speed comparison against LAMP and rt-PCR  
104 tests.

105

106 For the initial evaluation of each MCDA primer set, a 10  $\mu$ l reaction was used and contained:  
107 5  $\mu$ l of 2x WarmStart master mix, 0.2  $\mu$ l of fluorescent dye, 1.2  $\mu$ l of MCDA primer mix, 0.2  
108  $\mu$ l of 1U/ $\mu$ l Antarctic thermolabile UDG (NEB), 0.7  $\mu$ l of 10 mM dUTP, 1.7  $\mu$ l of H<sub>2</sub>O and 1  
109  $\mu$ l of 1000 copy/ $\mu$ l DNA template (final reaction concentration = 100 DNA copies/ $\mu$ l). The

110 final concentration of each MCDA primer in the reaction was 0.4  $\mu$ M of F1 and F2, 0.8  $\mu$ M  
111 of C1 and C2, 1.2  $\mu$ M of R1, R2, D1 and D2 and 2.4  $\mu$ M of CP1 and CP2. Specificity of  
112 MCDA primer sets were also evaluated using purified human genomic DNA (Sigma) and a  
113 microbial community DNA standard (Zymo Research). MCDA reactions were performed in  
114 triplicates in the Rotor-Gene Q (Qiagen) with isothermal amplification at either 60°C, 63°C or  
115 65°C for 1 h and real time fluorescence detection every 60 seconds, followed by enzyme  
116 inactivation at 95°C for 5 min and a final melt curve from 50°C – 99°C to ensure correct  
117 MCDA product.

118

### 119 **Comparison of MCDA, LAMP and rt-PCR**

120 To compare the speed and sensitivity (limit of detection) of MCDA, LAMP and rt-PCR,  
121 published primers targeting the same SARS-CoV-2 MCDA ORF1ab (NC\_045512.2: 416-  
122 931) and N (NC\_045512.2: 28246-28747) regions were used (Supplementary Table 1). For  
123 LAMP, two published primer sets from Zhang et al.<sup>3</sup> which targeted the same region as our  
124 MCDA were compared. For rt-PCR, there were no suitable published primers pairs which  
125 targeted the same ORF1ab region, therefore only primers submitted by the National Institute  
126 of Health, Thailand against the N gene was compared<sup>8</sup>. All primers were HPLC-purified  
127 grade.

128

129 MCDA, LAMP and rt-PCR were tested in three independent runs (biological replicates)  
130 using the same aliquot of DNA/RNA. Each run contained 3 technical replicates. The limit of  
131 detection was defined as the highest dilution where all 9 replicates (3 biological replicates x 3  
132 technical replicates) were detected.

133

134 To reduce between run variations, 10  $\mu$ l MCDA and LAMP reactions were set up and  
135 performed simultaneously in the same run. MCDA reactions were prepared as described  
136 above. For LAMP, each 10  $\mu$ l reaction contained: 5  $\mu$ l 2x WarmStart master mix (NEB), 0.2  
137  $\mu$ l 50x fluorescent dye (NEB), 0.2  $\mu$ l 1U/ $\mu$ l Antarctic thermolabile UDG (NEB), 0.7  $\mu$ l 10  
138 mM dUTP, 1  $\mu$ l LAMP primer mix, 1.9  $\mu$ l of H<sub>2</sub>O and 1  $\mu$ l of DNA/RNA template. Each  
139 LAMP primer mix contained 16  $\mu$ M FIP and BIP, 2  $\mu$ M F3 and B3 and 4  $\mu$ M LF and LB.  
140 The final concentration of each LAMP primer in the reaction was 1.6  $\mu$ M FIP and BIP, 0.2  
141  $\mu$ M F3 and B3 and 0.4  $\mu$ M LF and LB. MCDA and LAMP isothermal amplification was  
142 performed at 65°C as described above. The normalised fluorescence threshold line for N gene  
143 amplification was set above the background fluorescence at 0.2 for MCDA and LAMP. For  
144 ORF1ab MCDA and LAMP, the normalised fluorescence threshold line was set at 0.4 as  
145 background fluorescence was higher. The detection time for MCDA and LAMP was defined  
146 as the time it takes for the fluorescence intensity to pass the threshold line.

147

148 For rt-PCR using DNA templates, 10  $\mu$ l reactions containing 5  $\mu$ l SensiFAST probe No-ROX  
149 mix (Bioline), 0.5  $\mu$ l rt-PCR primer mix (40  $\mu$ M F and R, 10  $\mu$ M probe), 3.5  $\mu$ l of H<sub>2</sub>O and 1  
150  $\mu$ l DNA template were used. The final concentration of each rt-PCR primer and probe in the  
151 reaction was 2  $\mu$ M F and R and 0.5  $\mu$ M probe. The cycling conditions were 95°C for 2 min,  
152 followed by 45 cycles of 95°C for 15 secs and 55°C for 30 secs.

153

154 For rt-PCR with RNA templates, 10  $\mu$ l reactions were set up containing 5  $\mu$ l SensiFAST  
155 probe No-ROX One-Step mix (Bioline), 0.5  $\mu$ l primer mix (40  $\mu$ M F and R, 10  $\mu$ M probe),  
156 0.1  $\mu$ l reverse transcriptase (Bioline), 3.4  $\mu$ l of H<sub>2</sub>O and 1  $\mu$ l RNA template. Reverse  
157 transcription was performed at 45°C for 20 minutes followed by rt-PCR amplification as  
158 described above for DNA.

159

160 To compare the speed of rt-PCR, cycle threshold (Ct) was converted to time using the  
161 following equation:  $\text{Time} = (\text{Ct} \times 50 \text{ sec}) + 120 \text{ sec}$ . The detection time required for rt-PCR  
162 was calculated based on the cycling conditions (45 sec per cycle plus an initial 120 sec hold)  
163 and the ramp rate for the Rotor-gene Q (5 sec per cycle). The ramp rate for the Rotor gene Q  
164 is 15°C/s for heating and 20°C/s for cooling according to the manufacture's technical  
165 information ([https://www.qiagen.com/us/resources/download.aspx?id=2120af5e-8daf-4184-  
166 b277-aeb6ef5bbc05&lang=it-IT](https://www.qiagen.com/us/resources/download.aspx?id=2120af5e-8daf-4184-b277-aeb6ef5bbc05&lang=it-IT)).

167

## 168 **Results**

### 169 **Development of MCDA assays for SARS-CoV-2 detection**

170 Three 300 bp conserved regions suitable for MCDA primer design were identified from the  
171 genome alignment of 1,216 SARS-CoV-2 strains. Two regions, designated as region 1 and 2,  
172 belonged to the ORF1ab gene at NC\_045512.2 position 515-831 and 12968-13288  
173 respectively. One region, designated as region 3, corresponded to the N-gene at  
174 NC\_045512.2 position 28345-28647. Four MCDA primer sets for each region was designed  
175 and evaluated (Supplementary Table 1).

176

177 Each MCDA primer set was initially tested at 3 isothermal amplification temperatures (60°C,  
178 63°C and 65°C) using 1000 DNA copies/reaction as the starting template. As seen in Figure  
179 1, regardless of the primer sets used, the slowest amplification time was observed at 60°C.  
180 Amplification at 63°C and 65°C were similar and 65°C was chosen as the isothermal  
181 amplification temperature used.

182



183 To maintain MCDA assay robustness against SNPs which may affect MCDA primer binding  
184 and amplification efficiency, primer sets from two different regions were chosen for further  
185 development as a duplex assay. Amplification of region 2 was the slowest for all primer sets  
186 (Figure 1 D-F) compared with region 1 and 3, taking between 15-25 minutes at 65°C. Primer  
187 sets in region 2 also had very high variation between technical replicates (data not shown).  
188 Therefore region 2 was removed from further evaluation.

189

190 Region 3 amplification of the N gene was the fastest with primer set 2 followed closely by  
191 primer set 3 (Figure 1G-I). Primer set 1 and 4 were the slowest for region 3 and were  
192 therefore eliminated from further testing. We also observed that primer set 2 had tighter  
193 technical replicates compared to primer set 3 (data not shown), thus region 3 primer set 2 was  
194 chosen as our final MCDA primer set for further sensitivity and specificity testing.

195

196 Within region 1, primer set 3 was the slowest with fluorescence appearing at ~35 min (Figure  
197 1C). This primer set was removed from further consideration. Primer set 1 was the fastest  
198 primers to amplify region 1 and was chosen for inclusion in our MCDA assay.

199

200 Therefore, the final primer sets chosen for MCDA SARS-CoV-2 detection was region 1  
201 (ORF1ab) primer set 1 and region 3 (N gene) primer set 2 (Figure 2). Both primer sets  
202 showed no non-specific amplification when tested against human and microbial community  
203 genomic DNA.

204

205 **Sensitivity and time to detection comparison of MCDA, LAMP and rt-PCR**

206 The sensitivity and speed for MCDA, LAMP and rt-PCR were then compared for two SARS-  
207 CoV-2 genes. For the N gene (region 3), detection by MCDA was consistently faster than  
208 LAMP, by ~10-13 minutes, for most DNA dilutions tested (Table 1). The average fastest  
209 detection time for MCDA was 5.2 minutes at 10,000 copies/ $\mu$ l while for LAMP it was 15  
210 minutes. MCDA also had higher sensitivity with the limit of detection at 100 copies/ $\mu$ l while  
211 for LAMP it was 500 copies/ $\mu$ l. This limit of detection was equivalent to a rt-PCR Ct value  
212 of 32.4 and 30.3, respectively. A greater number of sporadic detections for higher dilutions  
213 were also observed for MCDA compared to LAMP. MCDA was also significantly faster than  
214 rt-PCR by ~20 minutes for lower dilutions and 10 minutes for higher dilutions. At 10,000  
215 copies/ $\mu$ l, the detection time for rt-PCR was 23 minutes. However, rt-PCR had the highest  
216 sensitivity with the limit of detection at 10 copies/ $\mu$ l and sporadic amplification at 1 copy/ $\mu$ l.  
217 Similar results were also observed using RNA template with rt-PCR being the most sensitive  
218 technique, detecting RNA at  $10^{-6}$  dilution. For MCDA, the lowest RNA dilution detected was  
219  $10^{-4}$ , with only sporadic detection for LAMP at this dilution.

220

221 For ORF1ab, LAMP was more sensitive than MCDA with the limit of detection at 50  
222 copies/ $\mu$ l and had more sporadic detection at higher dilutions (Table 2). The limit of  
223 detection for MCDA was 500 copies/ $\mu$ l. LAMP was also slightly faster than MCDA by ~1-3  
224 minutes for concentrations above the limit of detection. The fastest time to detection for  
225 ORF1ab LAMP was 8.4 minutes while for MCDA it was 9.7 minutes.

226

## 227 **Discussion**

228 Our results showed that MCDA is the fastest nucleic acid amplification method tested for  
229 SARS-CoV-2 detection with detection of the N gene as fast as 5 minutes. However, this was  
230 contingent on the gene targeted and the primer design with the NEB designed LAMP assay  
231 for ORF1ab<sup>3</sup> showing similar speed to our equivalent MCDA ORF1ab assay.

232

233 rt-PCR remains the most sensitive nucleic acid amplification method for SARS-CoV-2  
234 detection compared to MCDA and LAMP. This result is in agreement with previous LAMP  
235 SARS-CoV-2 assays which showed rt-PCR having greater sensitivity<sup>9,10</sup>. The limit of  
236 detection for our MCDA N gene assay was 100 copies/ $\mu$ l or an equivalent N gene average Ct  
237 value of 32.4 (Table 1). The median rt-PCR Ct value in 324 clinical COVID-19 samples from  
238 a range disease severity was found to be 31.15 in Singanayagam et al.<sup>11</sup> while in Passomsub  
239 et al.<sup>12</sup> the median N gene Ct value in saliva samples and nasopharyngeal/throat samples were  
240 31.8 and 30.5, respectively. This suggests that our MCDA assay has the potential to detect  
241 SARS-CoV-2 but with lower sensitivity and consistent with our comparison using synthetic  
242 templates. Furthermore, Lamb et al.<sup>7</sup> developed a COVID-19 LAMP assay with a limit of  
243 detection of 0.08 fg or an equivalent rt-PCR Ct value of 30.3 and were able to validate their  
244 LAMP assay in 19/20 positive clinical COVID samples. Our MCDA assay has increased  
245 sensitivity and speed compared to LAMP, suggesting that MCDA has the potential for similar  
246 applications as LAMP with better sensitivity and speed.

247

248 For MCDA, this is the first study to directly benchmark the speed and sensitivity of MCDA  
249 to rt-PCR against the same targets. Previous MCDA studies only compared gel-based PCR<sup>4</sup>,  
250 different rt-PCR gene targets<sup>13,14</sup> or used rt-PCR sensitivity results previously reported in

251 other studies<sup>4,5</sup> (as 100 copies in different studies may not be equivalent due to pipetting  
252 differences, differences in the method used to measure nucleic acid concentration (nanodrop  
253 vs qubit) or differences in machine calibration, etc.). In order to benchmark different nucleic  
254 acid techniques, we used and recommend the same reaction volume, same machine, same  
255 DNA standards and aliquots, and where possible the same run is used.

256

257 This study found that different nucleic acid amplification methods offer different advantages  
258 and this should be considered depending on the application. rt-PCR was the most sensitive  
259 method tested and should remain the gold standard for SARS-CoV-2 detection. However, the  
260 portable nature and speed of MCDA makes it suitable for settings where rt-PCR would be too  
261 slow. Although the fastest time to detection for MCDA is ~5 minutes, MCDA amplification  
262 should be performed for at least 20 minutes to ensure reliable results for negative samples  
263 while for rt-PCR, the current amplification time, not including reverse transcription, is 30-40  
264 minutes. Additionally, reverse transcription and amplification for MCDA and LAMP can  
265 occur simultaneously. This removes the need to sequentially perform an initial 20 min reverse  
266 transcription step prior to amplification as required for rt-PCR, making MCDA even faster.  
267 Therefore, it is estimated that the total time saved using MCDA compared to rt-PCR is 30-40  
268 minutes. An additional advantage of MCDA is that it uses the same Bst polymerase and  
269 reverse transcriptase as LAMP, which are more resistant against inhibitors than rt-PCR<sup>15</sup>.  
270 LAMP has been shown to amplify SARS-CoV-2 RNA extracted using simple extraction  
271 procedures such as boiling<sup>16-18</sup>. Therefore, it is anticipated that MCDA can also be used to  
272 detect SARS-CoV-2 RNA extracted using these same procedures.

273

274 MCDA (and other isothermal amplification methods) is less sensitive than rt-PCR, making it  
275 less attractive to develop it further as a clinical diagnostic test. However, there may be  
276 situations where these methods will be useful such as rapid screening of samples with high  
277 viral RNA content. The addition of a colorimetric dye instead of a fluorescent dye can  
278 further simplify MCDA for rapid screening. Further studies in a variety of settings will be  
279 required to determine where MCDA and other isothermal nucleic acid methods can offer an  
280 advantage in certain settings where rapid test turnaround time or test simplicity is paramount.

### 281 **Competing interests statement**

282 The authors declare no competing interests.

### 283 **Author Contributions**

284 RL conceived the study. LDWL performed the experiments, analysed the results and drafted  
285 the manuscript. MP performed the MCDA target selection and BLAST. XZ and LL designed  
286 the MCDA primers. All authors provided critical revision of the manuscript.

### 287 **Funding**

288 This work was supported by a UNSW school research grant.

### 289 **Data availability**

290 All data generated or analysed during this study are included in this published article (and its  
291 Supplementary Information files).

### 292 **References**

293 1 Corman, V. M. *et al.* Detection of 2019 novel coronavirus (2019-nCoV) by real-time  
294 RT-PCR. *Euro. Surveill.* **25**, 2000045, [10.2807/1560-7917.ES.2020.25.3.2000045](https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000045)  
295 (2020).

- 296 2 Guo, L. *et al.* Profiling early humoral response to diagnose novel coronavirus disease  
297 (COVID-19). *Clin. Infect. Dis.* **71**, 778-785 (2020).
- 298 3 Zhang, Y. *et al.* Rapid molecular detection of SARS-CoV-2 (COVID-19) virus RNA  
299 using colorimetric LAMP. *MedRxiv*, [10.1101/2020.02.26.20028373](https://doi.org/10.1101/2020.02.26.20028373) (2020).
- 300 4 Wang, Y. *et al.* Rapid and sensitive isothermal detection of nucleic-acid sequence by  
301 multiple cross displacement amplification. *Sci. Rep.* **5**, 11902, 10.1038/srep11902  
302 (2015).
- 303 5 Zhang, X., Payne, M., Wang, Q., Sintchenko, V. & Lan, R. Highly sensitive and  
304 specific detection and serotyping of five prevalent *Salmonella* serovars by multiple  
305 cross-displacement amplification. *J. Mol. Diagn.* **22**, 708-719, (2020).
- 306 6 Shu, Y. & McCauley, J. GISAID: Global initiative on sharing all influenza data –  
307 from vision to reality. *Euro. Surveill.* **22**, 30494, [10.2807/1560-](https://doi.org/10.2807/1560-7917.ES.2017.22.13.30494)  
308 [7917.ES.2017.22.13.30494](https://doi.org/10.2807/1560-7917.ES.2017.22.13.30494) (2017).
- 309 7 Lamb, L. E., Bartolone, S. N., Ward, E. & Chancellor, M. B. Rapid detection of novel  
310 coronavirus/Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by  
311 reverse transcription-loop-mediated isothermal amplification. *PLoS One* **15**,  
312 e0234682-e0234682, 10.1371/journal.pone.0234682 (2020).
- 313 8 World Health Organization. Molecular assays to diagnose COVID-19: summary table  
314 of available protocols. [https://www.who.int/publications/m/item/molecular-assays-to-](https://www.who.int/publications/m/item/molecular-assays-to-diagnose-covid-19-summary-table-of-available-protocols)  
315 [diagnose-covid-19-summary-table-of-available-protocols](https://www.who.int/publications/m/item/molecular-assays-to-diagnose-covid-19-summary-table-of-available-protocols) (2020).
- 316 9 Nagura-Ikeda, M. *et al.* Clinical evaluation of self-collected saliva by quantitative  
317 reverse transcription-PCR (RT-qPCR), direct RT-qPCR, reverse transcription-loop-  
318 mediated isothermal amplification, and a rapid antigen test to diagnose COVID-19. *J.*  
319 *Clin. Microbiol.* **58**, e01438-01420, 10.1128/JCM.01438-20 (2020).
- 320 10 Lee, J. Y. H. *et al.* Validation of a single-step, single-tube reverse transcription loop-  
321 mediated isothermal amplification assay for rapid detection of SARS-CoV-2 RNA. *J.*  
322 *Med. Microbiol.* **69**, 1169-1178, (2020).
- 323 11 Singanayagam, A. *et al.* Duration of infectiousness and correlation with RT-PCR  
324 cycle threshold values in cases of COVID-19, England, January to May 2020. *Euro.*  
325 *Surveill.* **25**, 2001483, [10.2807/1560-7917.ES.2020.25.32.2001483](https://doi.org/10.2807/1560-7917.ES.2020.25.32.2001483) (2020).
- 326 12 Pasomsub, E. *et al.* Saliva sample as a non-invasive specimen for the diagnosis of  
327 coronavirus disease 2019: a cross-sectional study. *Clin. Microbiol. Infect.*,  
328 [10.1016/j.cmi.2020.05.001](https://doi.org/10.1016/j.cmi.2020.05.001) (2020).

- 329 13 Wang, Y. *et al.* Establishment and application of a multiple cross displacement  
330 amplification coupled with nanoparticle-based lateral flow biosensor assay for  
331 detection of *Mycoplasma pneumoniae*. *Front. Cell. Infect. Microbiol.* **9**, 325,  
332 10.3389/fcimb.2019.00325 (2019).
- 333 14 Zhao, F. *et al.* Establishment and application of multiple cross displacement  
334 amplification coupled with lateral flow biosensor (MCDA-LFB) for visual and rapid  
335 detection of *Candida albicans* in clinical samples. *Front. Cell. Infect. Microbiol.* **9**,  
336 102, 10.3389/fcimb.2019.00102 (2019).
- 337 15 Kaneko, H., Kawana, T., Fukushima, E. & Suzutani, T. Tolerance of loop-mediated  
338 isothermal amplification to a culture medium and biological substances. *J. Biochem.*  
339 *Biophys. Methods* **70**, 499-501 (2007).
- 340 16 Dao Thi, V. L. *et al.* A colorimetric RT-LAMP assay and LAMP-sequencing for  
341 detecting SARS-CoV-2 RNA in clinical samples. *Sci. Transl. Med.* **12**, eabc7075,  
342 10.1126/scitranslmed.abc7075 (2020).
- 343 17 Ganguli, A. *et al.* Rapid isothermal amplification and portable detection system for  
344 SARS-CoV-2. *Proc. Nat. Acad. Sci. U.S.A* **117**, 22727, 10.1073/pnas.2014739117  
345 (2020).
- 346 18 Lalli, M. A. *et al.* Rapid and extraction-free detection of SARS-CoV-2 from saliva by  
347 colorimetric reverse-transcription loop-mediated isothermal amplification. *Clin.*  
348 *Chem.*, 10.1093/clinchem/hvaa267 (2020).

349

## 350 **Figures**

351 **Figure 1:** Initial evaluation of MCDA primer sets at 3 different isothermal amplification  
352 temperature (60°C, 63°C and 65°C). Four MCDA primer sets were designed for each target  
353 region chosen. **A-C:** Region 1 ORF1ab: 515-831 **D-E:** Region 2 ORF1ab: 12968-13288 **F-H:**  
354 Region 3 N gene:28345-28647.

355

356 **Figure 2:** The nucleotide sequences and position of the final (A) ORF1ab and (B) N gene  
357 COVID-19 MCDA primer sets chosen in this study. Right and left arrows show sense and  
358 complementary sequences, respectively while coloured text indicate the position of primers:

359 F1/F2 displacement primers in purple, P1/P2 primers in green, C1/C2 amplification primers  
360 in blue, D1/D2 amplification primers in yellow and R1/R2 amplification primers in red.



361

## Tables

362

Table 1: Comparison of the sensitivity and time to detection for MCDA, LAMP and rt-PCR targeting the N gene from 3 independent runs.

DNA copies per $\mu$ l	MCDA average detection time (min)	MCDA reps <sup>\$</sup>	LAMP average detection time (min)	LAMP reps <sup>\$</sup>	rt-PCR average Ct value	rt-PCR average detection time (min)	rt-PCR rep <sup>\$</sup>
1	NA	NA	NA	NA	43.93 $\pm$ 1.34	38.61 $\pm$ 1.11	3/9
10	19.3 $\pm$ 17.6	5/9	20.9 $\pm$ 0.4	2/9	<b>35.5 <math>\pm</math>0.6*</b>	<b>31.6 <math>\pm</math>0.47*</b>	<b>9/9*</b>
25	20.4 $\pm$ 22.4	4/9	26.7 $\pm$ 11.4	3/9	34.2 $\pm$ 0.03	30.5 $\pm$ 0.03	9/9
50	7.8 $\pm$ 1	6/9	20.3 $\pm$ 1	6/9	33.0 $\pm$ 0.25	29.5 $\pm$ 0.21	9/9
100	<b>10.2 <math>\pm</math>3.2*</b>	<b>9/9*</b>	23.5 $\pm$ 8.6	5/9	32.4 $\pm$ 0.22	29.0 $\pm$ 0.19	9/9
5,00	6.5 $\pm$ 0.1	9/9	<b>17.5 <math>\pm</math>0.6*</b>	<b>9/9*</b>	30.3 $\pm$ 0.68	27.3 $\pm$ 0.57	9/9
1,000	6.2 $\pm$ 0.2	9/9	17.3 $\pm$ 0.7	9/9	29.2 $\pm$ 0.26	26.3 $\pm$ 0.22	9/9
10,000	5.2 $\pm$ 0.1	9/9	15.0 $\pm$ 0.4	9/9	25.7 $\pm$ 0.06	23.4 $\pm$ 0.05	9/9

363

NA = no amplification detected

364

\*Limit of detection

365

<sup>\$</sup> reps: 3 runs with 3 technical replicates = 9 replicates.

366

367 Table 2: Comparison of the sensitivity and time to detection for MCDA and LAMP targeting ORF1ab from 3 independent runs.

DNA copies per reaction	MCDA average detection time (min)	MCDA reps <sup>\$</sup>	LAMP average detection time (min)	LAMP reps <sup>\$</sup>
10	55.3	1/9	17.1 ±6.3	3/9
25	46.4 ±15	3/9	11.8 ±0.5	5/9
50	20.2 ±9	8/9	<b>12.2 ±2.1*</b>	<b>9/9*</b>
100	13.6 ±3.9	6/9	10.4 ±0.8	8/9
500	<b>12.6 ±1.3*</b>	<b>9/9*</b>	9.7 ±0.2	9/9
1,000	11.2 ±0.3	9/9	9.5 ±0.1	9/9
10,000	9.7 ±0.3	9/9	8.4 ±0.1	9/9

368 \*Limit of detection

369 <sup>\$</sup> reps: 3 runs with 3 technical replicates = 9 replicates.

370

371 **Supplementary Materials**

372 **Supplementary Table 1:** List of MCDA, LAMP and rt-PCR primers used in this study. Bolded MCDA primer names are primers shared  
373 between 2 or more primer sets. \* indicate primers used in rt-PCR for confirmation of complete DNA removal from transcribed RNA. Red text  
374 indicates the final primer sets chosen for the MCDA SARS-CoV-2 assay.

375 **Supplementary Table 2:** List of synthesised gene fragments used as DNA/RNA template for MCDA, LAMP and rt-PCR. Blue indicates  
376 universal M13 adapters while red depicts the sequence for T7 promoter.



